View clinical trials related to Unknown Primary Neoplasms.
Filter by:Primary objectives: 1. To determine the overall tumor response rate with oxaliplatin in combination with gemcitabine (GEMOX) as first line and second line therapy in unknown primary cancer (UPC). 2. To determine the tolerability (toxicity) of this regimen in this patient population. Secondary objectives: 1. To determine the median overall survival (OS) and time to progression (TTP) for patients treated with this combination. 2. To determine the impact of this combination on quality of life (QOL) in this patient population.